Nyxoah has secured financing commitments of up to $77 million to support the U.S. commercialization of its innovative Genio system for treating Obstructive Sleep Apnea.

Target Information

Nyxoah SA, based in Mont-Saint-Guibert, Belgium, is a prominent medical technology company dedicated to creating innovative solutions for the treatment of Obstructive Sleep Apnea (OSA) through neuromodulation. The company's flagship product, the Genio system, offers a leadless and battery-free hypoglossal neurostimulation therapy aimed at alleviating OSA, a prevalent sleep disorder linked to significant health risks, including cardiovascular complications and increased mortality rates.

Having achieved considerable recognition, the Genio system secured its European CE Mark in 2019 following the successful BLAST OSA study and has expanded its therapeutic indications to include Complete Concentric Collapse (CCC) patients. Furthermore, the device received FDA approval in August 2025, solidifying Nyxoah's position as a leader in OSA treatment innovations.

Industry Overview in Belgium

The medical technology industry in Belgium is renowned for its robust regulatory framework and high standards of innovation, making it a fertile ground for emerging companies like Nyxoah. The nation boasts a strong network